AAAlfred Asante‐Korang

Alfred Asante‐Korang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alfred Asante‐Korang has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Jennifer Carapellucci

    Division of Pediatric Cardiology Johns Hopkins All Children's Hospital Saint Petersburg Florida USA

    4 shared publications
  • Diane Krasnopero

    Division of Cardiology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA

    3 shared publications
  • James K. Kirklin

    Kirklin Institute for Research in Surgical Outcomes University of Alabama at Birmingham Birmingham Alabama USA

    3 shared publications
  • Shahnawaz Amdani

    Division of Cardiology & Cardiovascular Medicine, Cleveland Clinic Children's, Cleveland, Ohio

    3 shared publications
  • Awais Ashfaq

    Johns Hopkins All Children’s Heart Institute, Johns Hopkins All Children’s Hospital, St. Petersburg, FL

    2 shared publications
  • Brian Brown

    Division of Pharmacy, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA

    2 shared publications

Latest Publications

  • Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia

    by Zsuzsanna Gaál, Cristina Meehan, Melis Yilmaz, Boglarka Ujhazi, Paola Suhet, Rahim Miller, Joseph Dasso, Kranthi Nomula, Brady Franson, Marta Toth, et al.

  • Addressing Healthcare Disparities in Pediatric Thoracic Transplantation: A Blueprint for Change

    by Jake Kleinmahon, Valerie Chepp, Samantha J. Anthony, Jeffrey G. Gossett, Simon Urschel, Christian Benden, Alfred Asante‐Korang, Shahnawaz Amdani

    Outcomes in pediatric thoracic transplantation have significantly improved, yet stark inequities persist. Disparities arise from biases in the healthcare system toward racial, ethnic, or religious groups as well as LGBTQ+ patients and families. Furthermore, geographic and socioeconomic factors and other social determinants of health also play an important role in outcomes. While the impact of these disparities on pediatric transplant recipients has been previously reported, a comprehensive approach to address these root causes is lacking. This article reviews the existing literature on the origins and manifestations of healthcare disparities in pediatric thoracic transplantation. Building upon this analysis, we then propose a blueprint for change, outlining actionable strategies to address the identified causes of inequity and, ultimately, improve outcomes for all pediatric thoracic transplant patients.

  • Long‐Term Survival in Children Following Heart Transplantation

    by Emily A. Hayes, Devin Koehl, Ryan Cantor, Lauren A. Fisher, Estela Azeka, Deepa Mokshagundam, Alfred Asante‐Korang, Paolo Rusconi, Matthew J. O'COnnor, Deipanjan Nandi, et al.

    Background: Short‐term outcomes following heart transplantation in children have improved, but comparable improvements in long‐term survival continues to have barriers. We sought to investigate long‐term outcomes following heart transplantation and to identify protective and risk factors associated with long‐term survival in children.Methods: The Pediatric Heart Transplant Society (PHTS) database was queried for heart transplant recipients from 1993 to 2010 who were ≤ 10 years of age at time of transplant. Patients with conditional graft survival > 3 years and at ≥ 10 years were analyzed. Survival and time‐to‐event were compared using the Kaplan–Meier method with a log‐rank test for significance. Factors associated with graft loss were identified using Cox proportional hazard modeling.Results: There were 1610 patients ≤ 10 year of age who were transplanted between 1993 and 2010 with conditional survival to 3 years post‐transplant. Of those patients, there were 1170 with conditional survival to 10 years post‐transplant. Patients < 1 year at transplant had improved survival compared to other age groups. Risk factors for graft loss after 3 years post‐transplant were malignancy, rejection, cardiac allograft vasculopathy (CAV), age, congenital heart disease, female sex, and Black race (p value for all < 0.05).Conclusions: Heart transplantation remains an effective therapy in children with a growing number of long‐term survivors. Risk factors for mortality in patients ≤ 10 years of age at transplant with conditional survival to 3 years post‐transplant include CAV, rejection, malignancy, female sex, and Black race. Further studies are needed to understand the social and biologic causes of racial and sex disparities in pediatric transplant patients.


  • Open Access

    Review on clinician bias and its impact on racial and socioeconomic disparities in pediatric heart transplantation

    by Shahnawaz Amdani, Jeffrey G. Gossett, Valerie Chepp, Simon Urschel, Alfred Asante‐Korang, Jarrod E. Dalton

    This expert review seeks to highlight implicit bias in health care, transplant medicine, and pediatric heart transplantation to focus attention on the role these biases may play in the racial/ethnic and socioeconomic disparities noted in pediatric heart transplantation. This review breaks down the transplant decision making process to highlight points at which implicit bias may affect outcomes and discuss how the science of human decision making may help understand these complex processes.


  • Three decades of collaboration through the Pediatric Heart Transplant Society Registry: A journey through registry data with a highlight on children with single ventricle anatomy

    by Marc E. Richmond, Jennifer Conway, James K. Kirklin, Ryan S. Cantor, Devin A. Koehl, Ashwin K. Lal, Nancy McDonald, Robert Gajarski, Kimberly Y. Lin, Rakesh K. Singh, et al.

    Background: The Pediatric Heart Transplant Society (PHTS) Registry was founded 30 years ago as a collaborative effort among like‐minded providers of this novel life‐saving technique for children with end‐stage heart failure. In the intervening decades, the data from the Registry have provided invaluable knowledge to the field of pediatric heart transplantation. This report of the PHTS Registry provides a comprehensive look at the data, highlighting both the longevity of the registry and one unique aspect of the PHTS registry, allowing for exploration into children with single ventricle anatomy.Methods: The PHTS database was queried from January 1, 1993 to December 31, 2019 to include pediatric (age < 18 years) patients listed for HT. For our analysis, we primarily analyzed patients by era. The early era was defined as children listed for HT from January 1, 1993 to December 31, 2004; middle era January 1, 2005 to December 31, 2009; and recent era January 1, 2010 to December 31, 2019. Outcomes after listing and transplant, including mortality and morbidities, are presented as unadjusted for risk, but compared across eras.Results: Since 1993, 11 995 children were listed for heart transplant and entered into the PHTS Registry with 9755 listed during the study period. The majority of listings occurred within the most recent era. Waitlist survival improved over the decades as did posttransplant survival. Other notable changes over time include fewer patients experiencing allograft rejection or infection after transplant. Waitlist and posttransplant survival have changed dramatically in patients with single ventricle physiology and significantly differ by stage of single ventricle palliation.Summary: Key points from this PHTS Registry summary and focus on patients with single ventricle congenital heart disease in particular, include the changing landscape of candidates and recipients awaiting heart transplant. There is clear improvement in waitlist and transplant outcomes for children with both cardiomyopathy and congenital heart disease alike.


  • Risk factors for 1‐year allograft loss in pediatric heart transplant patients using machine learning: An analysis of the pediatric heart transplant society database

    by Bethany L. Wisotzkey, Byron Jaeger, Alfred Asante‐Korang, Molly Brickler, Ryan S. Cantor, Melanie D. Everitt, James K. Kirklin, Devin Koehl, Benjamin S. Mantell, Philip T. Thrush, et al.

    Background: Pediatric heart transplant patients are at greatest risk of allograft loss in the first year. We assessed whether machine learning could improve 1‐year risk assessment using the Pediatric Heart Transplant Society database.Methods: Patients transplanted from 2010 to 2019 were included. The primary outcome was 1‐year graft loss free survival. We developed a prediction model using cross‐validation, by comparing Cox regression, gradient boosting, and random forests. The modeling strategy with the best discrimination and calibration was applied to fit a final prediction model. We used Shapley additive explanation (SHAP) values to perform variable selection and to estimate effect sizes and importance of individual variables when interpreting the final prediction model.Results: Cumulative incidence of graft loss or mortality was 7.6%. Random forests had favorable discrimination and calibration compared to Cox proportional hazards with a C‐statistic (95% confidence interval [CI]) of 0.74 (0.72, 0.76) versus 0.71 (0.69, 0.73), and closer alignment between predicted and observed risk. SHAP values computed using the final prediction model indicated that the diagnosis of congenital heart disease (CHD) increased 1 year predicted risk of graft loss by 1.7 (i.e., from 7.6% to 9.3%), need for mechanical circulatory support increased predicted risk by 2, and single ventricle CHD increased predicted risk by 1.9. These three predictors, respectively, were also estimated to be the most important among the 15 predictors in the final model.Conclusions: Risk prediction models used to facilitate patient selection for pediatric heart transplant can be improved without loss of interpretability using machine learning.


  • Optimal Donor Allograft Function: The Search for the Lowest Acceptable Donor Left Ventricular Ejection Fraction in Pediatric Heart Transplantation

    by Elizabeth S. Masotti, John M. Morrison, Jamie L. Fierstein, Awais Ashfaq, Jennifer Bsn Carapellucci, Racha Khalaf, Jessica A. Laks, Alexandra Miller, Ernest K. Amankwah, Alfred Asante-Korang

    Background.: The availability of heart donors is limited by organ shortage. Due to concerns of reduced survival, donors with depressed left ventricular ejection fraction (LVEF 50% (92.1%; CI, 91.4%-92.9%). Survival for the LVEF 45%–49% (88.8%; CI, 72.9%-95.7%) cohort was slightly lower than the ≥50% cohort, albeit nonsignificant. Conclusions.: One-year survival among pediatric heart transplants using a donor heart LVEF threshold of 45% or 40% was similar to a threshold of 50%. However, the finding is based on a small number of patients with LVEF <50%, and future larger prospective studies are warranted to confirm the findings of this study before a lower LVEF threshold is considered.


  • Survival analysis for pediatric heart transplant patients using a novel machine learning algorithm: A UNOS analysis

    by Awais Ashfaq, Geoffrey M. Gray, Jennifer Carapelluci, Ernest K. Amankwah, Mohamed Rehman, Michael Puchalski, Andrew Smith, James A. Quintessenza, Jessica Laks, Luis M. Ahumada, et al.


  • Diagnostic and management roles of FDG PET/CT imaging in post‐transplant lympho‐proliferation in pediatric heart transplantation

    by Abdel‐Karim Brown, Jennifer Carapellucci, Benjamin Oshrine, Anthony Gomez, Avner Meoded, Alfred Asante‐Korang

    Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of pediatric heart transplant (PHTx). 18F-FDG PET/CT has been used to differentiate early lympho-proliferation from more advanced PTLD. We report our experience with PET/CT in the management of PTLD following PHTx. This was a retrospective study of 100 consecutive PHTx recipients at our institution between 2004 and 2018. Patients who underwent PET/CT or conventional CT scans to evaluate for PTLD or high Epstein-Barr viral load were included. Males, eight females. Median age at transplant was 3.5 months (IQR = 1.5-27.5). Median age at PTLD diagnosis was 13.3 years (IQR = 9.2-16.1). Median time between transplant and PTLD diagnosis was 9.5 (IQR = 4.5-15) years. Induction agents were used in 12 patients (50%): Thymoglobulin (N = 9), anti-IL2 (N = 2), and Rituximab (N = 1). Eighteen patients (75%) had PET/CT, of whom 14 had 18FDG-avid PTLD. Six had conventional CT. Nineteen patients (79.2%) had diagnostic biopsy confirmation of PTLD, and 5 (20.8%) had excisional biopsies. Two patients had Hodgkin's lymphoma; nine had monomorphic PTLD; eight had polymorphic PTLD; five were classified as other. Nine patients had monomorphic PTLD, including seven with diffuse large cell lymphoma (DLBC) and one with T cell lymphoma. The majority (16/24) had multi-site involvement at PTLD diagnosis, and PET/CT showed that 31.3% (5/16) had easily accessible subcutaneous nodes. Seventeen patients (overall survival 71%) underwent successful treatment without recurrence of PTLD. Of seven deaths (7/24, 29%), five had DLBC lymphoma, one had polymorphic PTLD and one had T-cell lymphoma. PET-CT allowed simultaneous anatomical and functional assessment of PTLD lesions, while guiding biopsy. In patients with multiple lesions, PET/CT revealed the most prominent and active lesions, improving diagnostic accuracy.